Core Viewpoint - The Japanese pharmaceutical index has declined by 3.9%, marking the largest drop among industry sub-indices on the Tokyo Stock Exchange, following Trump's announcement to seek significant reductions in drug prices [1] Industry Summary - The pharmaceutical sector in Japan is experiencing a notable downturn, with a 3.9% decrease in its index, indicating potential market volatility and investor concern regarding pricing policies [1]

Key Points - Trump is considering lowering U.S. drug prices to international levels [2] - Verizon reported Q1 2025 revenue of $33.5 billion, exceeding market expectations of $33.23 billion and last year's $33 billion. However, Verizon lost 289,000 monthly phone users, surpassing analysts' average estimate of 185,500 [3] - Amazon is rumored to be slowing down its data center expansion [4] - Trump Media & Technology Group, Crypto.com, and Yorkville America Digital have finalized an ETF issuance agreement [4] - Chevron's CEO stated that responses to trade issues have led to market expectations of reduced oil demand [4] - 3M reported Q1 2025 revenue of $6 billion, above market expectations of $5.76 billion but slightly below last year's $6.016 billion [4] - TSMC has reportedly received orders for 2nm chips from Intel [4] - General Electric is cutting costs to maintain performance guidance [4] - Private equity giant Thoma Bravo plans to acquire Boeing's Jeppesen for nearly $9 billion [4]

Core Viewpoint - The Trump administration is reportedly considering reducing U.S. drug prices to align with international levels [1] Group 1 - The potential policy change aims to address the high cost of prescription drugs in the United States [1] - This initiative may impact pharmaceutical companies' pricing strategies and profit margins [1] - Aligning drug prices with international standards could lead to significant savings for consumers [1]